Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

Exclusion Criteria

• - With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment.
• - As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV.
• - Active heart disease including myocardial infarction within the last 3 months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication or uncontrolled congestive heart failure
• - Prior allogeneic transplant requiring immunosuppressive therapy (Patients with prior allogeneic transplants who remain clinically stable for ≥ 2 weeks or more off immunosuppressive therapy, are eligible)
• - White blood cell count ≥ 100,000/mm3 (100x10*9/L)
• - Type 1 Diabetes or uncontrolled Type II Diabetes
• - HbA1C ≥8% or fasting blood glucose >160 mg/Dl (>8.9 mmol/L)
• - Baseline fasting total cholesterol >300 mg/dL (>7.75 mmol/L)